Spinal Muscular Atrophy Type 1Symptoms, Doctors, Treatments, Advances & More
Spinal Muscular Atrophy Type 1 Overview
Learn About Spinal Muscular Atrophy Type 1
- Spinal muscular atrophy 1
- Muscular atrophy, infantile
- Proximal spinal muscular atrophy type 1
- Proximal spinal muscular atrophy, type 1
- SMA type 1
- SMA type I
- SMA, infantile acute form
- SMA-I
- SMA1
- Werdnig Hoffmann disease
- Werdnig-Hoffmann disease
Giovanni Baranello practices practicing medicine in London, United Kingdom. Mr. Baranello is rated as an Elite expert by MediFind in the treatment of Spinal Muscular Atrophy Type 1. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Spinal Muscular Atrophy Type 1, Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis, and Muscle Atrophy.
Riccardo Masson practices practicing medicine in Milan, Italy. Mr. Masson is rated as an Elite expert by MediFind in the treatment of Spinal Muscular Atrophy Type 1. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Spinal Muscular Atrophy Type 1, Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis, and Muscle Atrophy.
Department Of Neurology
Basil Darras is a Pediatric Neurologist practicing medicine in Boston, Massachusetts. Dr. Darras is rated as an Elite provider by MediFind in the treatment of Spinal Muscular Atrophy Type 1. He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis, Spinal Muscular Atrophy Type 2, Spinal Muscular Atrophy Type 1, and Gastrostomy. Dr. Darras is currently accepting new patients.
Summary: GB221 is a gene therapy that delivers a working SMN1 gene to the motor neurons of people with spinal muscular atrophy (SMA) Type 1. This study will evaluate the safety, tolerability and efficacy of GB221 in two groups: 1. participants aged from 2 weeks to younger than 12 months presenting with symptoms of SMA Type 1 who have never received a treatment OR are receiving the drug risdiplam 2. partici...
Summary: The study will evaluate safety and efficacy of intrathecal delivery of GC101 gene therapy drug as a treatment of spinal muscular atrophy Type 1 (SMA 1) patients.
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center